Therapeutic potential of TAS-115 in 3D breast cancer models
Biofabrication, vol.18, no.1, 2025 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 18 Issue: 1
- Publication Date: 2025
- Doi Number: 10.1088/1758-5090/ae2400
- Journal Name: Biofabrication
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Compendex, INSPEC, MEDLINE
- Keywords: 3D models, bioprinting, breast cancer, heterotypic spheroids
- Akdeniz University Affiliated: Yes
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. TAS-115, a multi-receptor tyrosine kinase inhibitor, has not previously been evaluated in TNBC. Here, we investigated its therapeutic effects alone and in combination with doxorubicin (DOXO), using three-dimensional heterotypic spheroid models, including free-standing, bioprinted static, and perfused systems. TAS-115 significantly reduced cell proliferation and viability, enhanced apoptosis, and suppressed c-mesenchymal-epithelial transition/hepatocyte growth factor and PI3K/Akt/mTOR signaling. Combined treatment with DOXO further amplified these effects. In perfused bioprinted models, TAS-115 markedly inhibited tumor cell migration, highlighting its potential to limit metastatic behavior. These findings identify TAS-115 as a promising therapeutic strategy for TNBC, either as a monotherapy or in combination with chemotherapy.